Detailed results from PALM007 study: no clinical impact of tecovirimat against mpox clade 1
6 January 2025. Related: mpox.
2025
Tecovirimat news continues: Japan approval includes mpox indication
2 January 2025. Related: mpox.
Looking back through 2024 and forward to 2025…
1 January 2025. Related: Editorial, Special reports.
i-Base appeal: Q&A services and the website in 2025
1 January 2025. Related: Editorial, Special reports.
ART pipeline 2025: exciting dual long-acting combinations and the challenge of generic dolutegravir
1 January 2025. Related: Special reports, Conference reports, Pipeline report, Antiretrovirals.
Transient impact of lenacapavir against MDR HIV-2 without other active ART
1 January 2025. Related: Antiretrovirals, Treatment strategies, Virology, Drug resistance.
Lenacapavir submitted to the US FDA with an indication for HIV PrEP
1 January 2025. Related: Antiretrovirals, Treatment access, HIV prevention and transmission.